IF a rationally designed small-molecule allosteric FN3K activator — docked computationally into the solvent-exposed C-terminal lobe cavity (residues 163–309) of AlphaFold model AF-Q9H479-F1 (pLDDT 94.3), optimized to form a salt bridge with D234 and engage the F244-centered allosteric network, administered systemically at pharmacologically relevant doses (route TBD pending ADMET profiling) — is administered to aged C57BL/6J mice (18–24 months, both sexes), a tissue-targeted enrichment strategy favoring metabolically active organs (liver, kidney, lens),

THEN a measurable reduction in bulk protein-bound fructosamine and advanced glycation end-product (AGE) burden — quantified by fluorometric AGE assay (≥25% reduction vs. vehicle), immunohistochemical staining for Nε-carboxymethyllysine (CML) and pentosidine crosslinks in liver and kidney tissue, and reduced glycated hemoglobin (HbA1c analog in mouse), alongside improved proteostasis metrics (HSP70/HSP90 chaperone load reduction, improved soluble-to-insoluble protein ratio in aged tissue lysates) — will be observed within a 12-week treatment window,

BECAUSE the following causal chain connects the intervention to the outcome:

1. Protein glycation accumulates irreversibly on long-lived proteins (collagen, lens crystallins, albumin, intracellular enzymes) as a function of age and metabolic stress; glucose-derived adducts such as fructosamines form on lysine residues and progress to irreversible AGEs if not intercepted early (Structural Mechanism of Ring-Opening Reaction of Glucose by Human Serum Albumin)[https://doi.org/10.1074/jbc.m113.467027].

2. FN3K (UniProt Q9H479) is the primary mammalian deglycation enzyme that phosphorylates the C3-OH of fructosamine adducts on protein lysines, destabilizing the ketoamine linkage and enabling spontaneous hydrolytic release of the glycation mark — reversing already-accumulated damage rather than merely preventing new adduct formation (Crystal Structure of Human FN3K, PDB 8UE1)[https://www.rcsb.org/structure/8UE1].

3. FN3K adopts a kinase-like two-lobe architecture (N-lobe residues 1–127; C-lobe residues 163–309) that undergoes substrate-induced hinge-closing motion to juxtapose ATP (bound via P-loop residues F39, K41, E55) and the glycated substrate lysine for phosphoryl transfer; the orthosteric catalytic residues D217, W219, F252, H288, H291, N287, and F292 coordinate substrate positioning (Structural basis for FN3K-mediated protein deglycation)[https://pmc.ncbi.nlm.nih.gov/articles/PMC11455621/].

4. An allosteric communication network centered on residue F244 in the C-terminal lobe transmits conformational information along the pathway F283→Q176→H288→N287→D217→F252, coupling distal pocket occupancy to the catalytic center geometry; D234 in this same lobe participates in Mg²⁺ coordination critical for ATP positioning, making it an anchor for a salt-bridge-forming activator pharmacophore (Ancestral protein reconstruction reveals substrate specificity mech...

SENS category: GlycoSENS

Key references: • doi.org/10.1074/jbc.m113.467027].